News | November 25, 2025
Abbott to acquire Exact Sciences for $21 billion
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The proposed transaction will be effected as a share swap
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The company will soon be launching a new portfolio of products in this segment
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Subscribe To Our Newsletter & Stay Updated
